(S)-pindolol benzoate

Actimed Therapeutics is testing (S)-pindolol benzoate (ACM-001.1, scientific name espindolol's single active enantiomer) on top of semaglutide to stop obese patients from losing muscle along with fat. The Phase 2 PROACT trial (NCT07101939) is recruiting 120 adults to see whether a single-enantiomer beta-blocker can preserve lean body mass during GLP-1 weight loss [1][2]. This is one of the first programs to take the muscle-loss problem with GLP-1s seriously enough to design a pharmacologic fix on top of the injection.

Not a novel chemical entity. ACM-001.1 is the (S)-enantiomer of pindolol, a beta-blocker first approved by FDA in September 1982 as Visken (Sandoz) and still sold generically [10]. Actimed is repackaging the single active enantiomer as a benzoate salt, banking on cleaner pharmacology and IP runway around the formulation rather than novel chemistry. The likely regulatory route is 505(b)(2), which lets Actimed lean on the existing pindolol safety database rather than build one from scratch - useful for speed, but it does not by itself create durable market exclusivity. The PROACT Phase 2 program is recruiting now (NCT07101939) with a 120-patient target across two protocols. PROACT 1 runs the drug alongside ongoing semaglutide therapy; PROACT 2 looks at the post-semaglutide phase, when patients often regain weight as fat rather than muscle [2]. Dose arms and full randomization schema are not detailed in the public registry entry beyond two ACM-001.1 dose levels. No FDA designations have been disclosed: no breakthrough therapy, fast track, orphan, or accelerated approval status. That tracks with where this sits. Lean body mass preservation isn't a recognized FDA-approvable indication on its own, so the regulatory path is uncertain even if the data read out cleanly. A Phase 1 bioavailability study (NCT06028321, n=51) wrapped in 2024 and was published in J Cachexia Sarcopenia Muscle in late 2024, showing the (S)-enantiomer benzoate salt has the PK behavior Actimed wanted [1][3]. PROACT readout timing isn't officially disclosed. Given recruitment opening in 2025 and a 120-patient LBM endpoint that needs several months of dosing, top-line is plausibly late 2026 or into 2027.

Two things happen when you give someone semaglutide: patients eat less and lose weight, but a meaningful fraction of that weight is lean tissue (muscle, organ mass, bone), not just fat. The cleanest published quantification comes from Regeneron's COURAGE trial readout, which estimated roughly 35% of semaglutide-induced weight loss was lean mass over 26 weeks [4]. That matters because muscle is what keeps older or sicker patients functional, and once a patient stops the drug the fat tends to come back faster than the muscle does. ACM-001.1 (scientific name espindolol - the (S)-enantiomer of pindolol formulated as the benzoate salt) tries to fix this with two asymmetric pharmacology levers in one molecule. The beta-1 adrenergic receptor is primarily cardiac [5]; blocking it suppresses systemic sympathetic overdrive, lowering circulating catecholamine tone that broadly promotes energy mobilization and proteolysis. So the beta-1 arm is an indirect, systemic anti-catabolic signal, not a direct muscle-wasting block. The beta-2 adrenergic receptor sits on skeletal muscle, where partial activation stimulates protein synthesis. (This is why clenbuterol, a full beta-2 agonist, is illegal in livestock and bodybuilding.) Espindolol delivers a weaker version of that anabolic push without the cardiac stimulation of a full agonist. Validation is mixed but not nothing. The same compound, then called MT-102, hit its primary endpoint in the ACT-ONE Phase 2 cancer cachexia trial: high-dose espindolol produced +0.54 kg/4 weeks weight gain (95% CI 0.38-0.70) versus −0.21 kg/4 weeks on placebo (P<0.0001), with lean mass driving most of the gain [6]. Beta-blockers as a class have shown anti-catabolic effects in heart failure cachexia. But cancer cachexia and GLP-1-induced muscle loss are different physiology: cachexia is driven by inflammatory cytokines, while GLP-1 muscle loss is driven by caloric restriction and reduced muscle loading. Whether the same drug works in both contexts is the open biological question.

PROACT (NCT07101939) is a Phase 2, two-part trial with 120 patients split across PROACT 1 and PROACT 2 [2]. PROACT 1 adds two doses of ACM-001.1 to patients actively on semaglutide; PROACT 2 covers the post-semaglutide weight-regain window. Primary endpoint: change in lean body mass, measured by DXA (a full-body X-ray scan that quantifies fat versus lean tissue). Two design concerns. First, 120 patients across two protocols means roughly 60 per arm. That's adequate for a clean DXA signal but tight for any functional secondary endpoint like grip strength or 6-minute walk distance. If LBM moves but functional measures don't, regulators and payers will ask whether the body composition change actually matters to patients. Second, the comparator and randomization structure isn't fully detailed in the public registry entry. The standard would be placebo plus semaglutide with stratification by baseline LBM and BMI. Without that, distinguishing drug effect from regression to the mean and from baseline imbalance gets harder. Recruitment is active as of mid-2026 [2]. Sponsor is Actimed alone, a small UK-based private company. Trial execution is probably a bigger risk than design here. A small biotech running a multi-site obesity adjunct trial against the gravity of well-funded GLP-1 incumbents needs both money and bandwidth to enroll on schedule and run good data quality at every site.

Our model estimates a 5% chance this drug is eventually approved. That starting point is the historical approval rate for Phase 2 drugs in this area - about 35% - which the model then adjusts based on ten specific facts about the trial and sponsor. The estimate falls well below that baseline mainly because of heavier-than-usual blinding, a weak sponsor approval record, limited earlier-phase results, and a randomized trial design. The remaining factors were close to average for this stage, so they had little effect on the final number.

Efficacy risk is the largest. PROACT could hit lean body mass but miss functional secondary endpoints. Without a strength or mobility improvement, the regulatory case weakens and payers will ask why anyone should add another daily pill to an already-expensive GLP-1 regimen. The 120-patient size is fine for DXA but thin for functional readouts. Safety risk is moderate. Beta-1 antagonism causes fatigue, bradycardia (slow heart rate), and exercise intolerance in some patients. Beta-2 partial agonism can cause tremor and tachycardia. The bet is that combining the two produces a net acceptable profile in obese patients on semaglutide. But these patients often carry baseline cardiometabolic complexity, so cardiac AEs need close monitoring. Pindolol also has agonist activity at the 5-HT1A serotonin receptor, which complicates the side-effect picture when combined with the appetite-suppression effects of GLP-1s. Execution risk is real. Actimed has raised roughly £20M to date - about £10M seed plus a Series A and 2023 extension totalling £9.75M, with Mankind Pharma a key strategic investor [11]. That is enough to start a 120-patient Phase 2 but probably not enough to fully fund through readout, contingency, and a Phase 3 launch without another raise or a partnership. Any cash gap means timeline slip and lost optionality. IP and commercial risk: pindolol has been generic since the 1990s. Actimed's protection therefore derives from the enantiomer-specific benzoate salt formulation and presumably method-of-use claims around the GLP-1 adjunct indication. Formulation patents are historically thin against ANDA challengers, and method-of-use claims around an indication route require physicians to actually prescribe by indication. Combined with the 505(b)(2) pathway giving at most 3 years of marketing exclusivity, IP durability is a real investor question for any commercial product. Even with positive data, the muscle-preservation add-on market is undefined. Lilly and Novo both have internal programs aimed at the same problem and would prefer to own the combination story rather than license a third-party adjunct. If ACM-001.1 works, Actimed becomes a buyout target rather than a standalone commercial player. If an incumbent already has a working internal asset, Actimed loses the deal.

Worth watching, with low expectations and a defined signal threshold. The data point that would matter: PROACT showing a clinically meaningful LBM preservation (something like a >50% reduction in semaglutide-associated lean mass loss vs placebo) plus at least one positive functional secondary endpoint. Anything less than both keeps the story speculative. Check back late 2026 through 2027 for PROACT top-line. In the meantime, two adjacent signals matter for the category as a whole: bimagrumab's Phase 2b obesity readouts at Lilly [8] and Regeneron's COURAGE trevogrumab/garetosmab data with semaglutide [9]. Both reading positive would validate the muscle-preservation thesis and pull Actimed up with them; both failing would gut the category and make ACM-001.1's path much harder regardless of its own data. Actimed itself is a thin sponsor: small UK private, ~£20M raised lifetime [11], with Mankind Pharma a strategic backer but no big pharma development partner disclosed. The asset's real value is as M&A bait for one of the GLP-1 incumbents looking for a cheap oral adjunct to a multi-billion-dollar injectable franchise - though formulation-patent fragility and the 505(b)(2) exclusivity ceiling mean the buyer would need to value the data and the head start more than the IP itself.